Amphastar Pharmaceuticals

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures and sells inhalation and intranasal products.[3]

Amphstar Pharmaceuticals, Inc.
Public
Traded as
Industrypharmaceutical industry 
HeadquartersRancho Cucamonga, California, United States
Key people
  • Mary Z. Luo
  • (Chairman of the Board)
  • Jack Yongfeng Zhang
  • (CEO)
Revenue US$ 240.18 million (2017)
US$ -895 thousand (2017)
US$ -4.51 million (2017)
Total assets US$ 454.67 million (2017)
Total equity US$ 337.33 million (2017)
Number of employees
~2000
WebsiteAmphastar.com
Footnotes / references
[1]

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]

References
  1. "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved June 27, 2018.
  2. "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  3. "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
  4. Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
  5. Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.